Results 221 to 230 of about 155,269 (289)

The combination of exercise and psychedelics for the treatment of major depressive disorder. [PDF]

Discov Ment Health
Fabiano N, Stubbs B, Lawrence DW, Rosenblat JD, Teixeira PJ, Wong S, Zhou C, Carhart-Harris R.   +7 more
europepmc   +1 more source

Safety, Tolerability, and Pharmacokinetics of GMDTC for Cadmium Poisoning: A Randomized Phase 1a/1b Trial

Clinical Pharmacology &Therapeutics, EarlyView.
Cadmium exposure causes serious health consequences; however, there is no clinically approved antidote for cadmium poisoning. This Phase 1a/1b trial aimed to investigate safety, tolerability, and pharmacokinetics of Sodium (S)‐2‐(dithiocarboxylato((2S,3R,4R,5R)‐2,3,4,5,6‐pentahydroxyhexyl) amino)‐4‐(methylthio) butanoate (GMDTC), a novel chelating ...
Xuefeng Ren, Wei Hu, Xiaobin Deng, Rong Ma, Fang Pei, Xushen Chen, Xuemei Wang, Jixin Tang, Yan Lai, Shangming Pan, Zhiyong Zhong, Sheng Fu, Huamin Yuan, Juan Yuan, Chuntao Huang, Yuan Zeng, Xiaodong Ying, Guanghui Dong, Jinxin Zhang, Jinyuan Zhao, Kangguang Lin, Xiaojiang Tang   +21 more
wiley   +1 more source

First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP1617, a Cathepsin-S Inhibitor, in Healthy Adult Subjects. [PDF]

Clin Transl Sci
Kojima T, Chen W, Smulders R, Stanhope S, Kowalski D, Heo N, Moy S, Goldston A, Han D, Zhu T.   +9 more
europepmc   +1 more source

Population Pharmacokinetics of Ticagrelor during Veno‐Arterial ECMO in Acute Coronary Syndrome: Model‐Informed Dosing Simulations

Clinical Pharmacology &Therapeutics, EarlyView.
Although patients with acute coronary syndrome supported by veno‐arterial extracorporeal membrane oxygenation (VA‐ECMO) have a high risk of thrombosis and bleeding, antiplatelet pharmacology in this setting is not well defined. This prospective observational study investigated the population pharmacokinetics of ticagrelor and its active metabolite AR ...
Soyoung Kang, Kyoung Lok Min, Seungwon Yang, Jongsung Hahn, Dasohm Kim, Byung Hak Jin, Soon Uk Chae, Soo Kyung Bae, Jin Wi, Min Jung Chang   +9 more
wiley   +1 more source

Bacteriophage pharmacodynamics studied in an <i>in vitro</i> pharmacokinetic model of infection. [PDF]

JAC Antimicrob Resist
Attwood MLG, Griffin P, Smorowinski P, Noel A, Haines M, Millard A, Adler K, Clokie M, Macgowan AP.   +8 more
europepmc   +1 more source

CYP2C19 Genotype is Associated with Citalopram Treatment Outcomes in a Real‐World Setting

Clinical Pharmacology &Therapeutics, EarlyView.
CYP2C19 metabolizes various selective serotonin reuptake inhibitors (SSRIs) and genetic CYP2C19 variants are associated with SSRI tolerability and response. Yet, whether CYP2C19 variability also impacts citalopram response remained unclear. We here evaluated associations between CYP2C19 genotypes and citalopram prescription data of 11,079 patients from
Yoomi Park, Yitian Zhou, Volker M. Lauschke   +2 more
wiley   +1 more source

Alcohol-medication interactions among older people: a narrative review on age-specific evidence. [PDF]

Alcohol Alcohol
Salis F, Belfiori M, Agabio R, Mandas A.
europepmc   +1 more source

PharmVar GeneFocus: CYP1A2—Clinical Impact, Genetic Variation, and Updated Nomenclature

Clinical Pharmacology &Therapeutics, EarlyView.
The Pharmacogene Variation Consortium (PharmVar) provides nomenclature for the highly polymorphic human CYP1A2 gene. CYP1A2 plays a crucial role in the biotransformation of several commonly used drugs, including antipsychotics, antidepressants, anxiolytics, and methylxanthines.
Katalin Monostory, Gonzalo Villapalos Garcia, Dora Koller, Solomon Adams, Chad A. Bousman, Evangelia Eirini Tsermpini, Michelle Whirl‐Carrillo, Amy J. Turner, Volker M. Lauschke, Mohamed Nagy, Erin C. Boone, Teri E. Klein, Pablo Zubiaur, Andrea Gaedigk   +13 more
wiley   +1 more source